Xenetic Biosciences is trading 5.49% down at $2.33 after no separate company announcement dated September 17 was identified to explain the after-hours decline.
- Closed September 17, 2026, at $2.46.
- On September 16, Xenetic proposed an all-stock Santersus acquisition; existing holders would own approximately 15% of the combined company.
- Available sources do not explicitly link the transaction to the move; broader markets were strongly higher.